Pentoxifylline

• Description:

  Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

• Product Name Alternative:

  BL-191; PTX; Oxpentifylline

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Autophagy; HIV; Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Autophagy; Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Pentoxifylline.html

• Purity:

  99.92

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |H2O : 93.3 mg/mL (ultrasonic; warming)

• Smiles:

  O=C(N1CCCCC(C)=O)N(C)C2=C(N(C)C=N2)C1=O

• Molecular Formula:

  C13H18N4O3

• Molecular Weight:

  278.31

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Iffat Hassan, et al. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014 Oct-Dec; 5 (4) : 510–516.|[2]A Ward, et al. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul;34 (1) :50-97.|[3]Yessica Cristina Castellanos-Esparza, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52 (4) :1246-1254.|[4]Shabnam Movassaghi, et al. Effect of Pentoxifylline on Ischemia- induced Brain Damage and Spatial Memory Impairment in Rat. Iran J Basic Med Sci. 2012 Sep-Oct; 15 (5) : 1083-1090.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [6493-05-6]